Drug intelligence / Profile preview

l-carnitine + simvastatin

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Inhalation

Overview

A combination therapy consisting of l-carnitine and simvastatin. L-carnitine is an amino acid derivative involved in fatty acid metabolism, while simvastatin is a statin that inhibits HMG-CoA reductase. When administered together, they demonstrate enhanced lipid-lowering effects compared to simvastatin alone, particularly for triglyceride reduction and lipoprotein(a) [Lp(a)] lowering. This combination creates a less atherogenic plasma lipid profile and may be particularly beneficial for patients with type 2 diabetes mellitus with hyperlipidemia.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on l-carnitine + simvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on l-carnitine + simvastatin.

Explore the full profile